References
- Ohishi T, Takahashi M, Kushida K, Horiuchi K, Ishigaki S, Inoue T. Quantitative analyses of urinary pyridinoline and deoxypyridinoline in patients with hyperthyroidism. Endocrine Res. 1992; 18: 281–290
- Seibel M J, Gartenberg F, Silverberg S J, Ratcliffe A, Robins S P, Bilezikian J P. Urinary hydroxypyridinium cross-links of collagen in primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 1992; 74: 481–486
- Robins S P, Black D, Paterson D R, Reid D M, Duncan A, Seibel M J. Evaluation of urinary hydroxypyridinium crosslink measurements as resorption markers in metabolic bone diseases. Eur. J. Clin. Invest. 1991; 21: 310–315
- Sano M, Kushida K, Takahashi M, Ohishi T, Kawana K, Okada M, Inoue T. Urinary pyridinoline and deoxypyridinoline in prostate carcinoma patients with bone metastasis. Br. J. Cancer 1994; 70: 701–703
- Lipton A, Demers L, Daniloff Y, Curley E, Hamilton C, Harvey H, Witters L, Seaman J, van der Giessen R, Seyedin S. Increased urinary excretion of pyridinium cross-links in cancer patients. Clin. Chem. 1993; 39: 614–618
- Ohishi T, Kushida K, Takahashi M, Kawana K, Yagi K, Kawakami K, Horiuchi K, Inoue T. Urinary bone resorption markers in patients with metabolic bone disorders. Bone 1994; 15: 15–20
- Uebelhart D, Schlemmer A, Johansen J S, Gineyts E, Christiansen C, Delmas P D. Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links. J. Clin. Endocrinol. Metab. 1991; 72: 367–373
- Fledelius C, Riis B J, Overgaad K, Christiansen C. The diagnostic validity of urinary free pyridinolines to identify women at risk of osteoporosis. Calcif. Tissue Int. 1994; 54: 381–384
- Mole P A, Walkinshaw M H, Robins S P, Paterson C R. Can urinary pyridinium crosslinks and urinary oestrogens predict bone mass and rate of bone loss after the menopause?. Eur. J. Clin. Invest. 1992; 22: 767–771
- Bonde M, Qvist P, Fledelius C, Riis B J, Christiansen C. Applications of an enzyme immunoassay for a new marker of bone resorption (crosslaps): follow-up on hormone replacement therapy and osteoporosis risk assessment. J. Clin. Endocrinol. Metab. 1995; 80: 864–868
- Garnero P, Hausherr E, Chapuy M-C, Marcelli C, Grandjean H, Muller C, Cormier C, Breart G, Meunier P J, Delmas P D. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS prospective study. J. Bone Miner. Res. 1996; 11: 1531–1538
- Takahashi M, Ohishi T, Aoshima H, Kushida K, Inoue T, Horiuchi K. Pre-fractionation with cation exchanger for determination of intermolecular crosslinks, pyridinoline and pentosidine, in hydrolysate. J. Liq. Chromatogr. 1993; 16: 1355–1370
- Kivirikko K I, Laitinen O, Prockop D J. Modifications of a specific assay for hydroxyproline in urine. Anal. Biochem. 1967; 19: 249–255
- Kin K, Kushida K, Yamazaki K, Okamoto S, Inoue T. Bone mineral density of the spine in normal Japanese subjects using dual-energy x-ray absorptiometry: Effect of obesity and menopausal status. Calcif. Tissue Int. 1991; 49: 101–106
- Dresner-Pollak R, Parker R A, Poku M, Thompson J, Seibel M J, Greenspan S L. Biochemical markers of bone turnover reflect femoral bone loss in erderly women. Calcif. Tissue Int. 1996; 59: 328–333
- Cosman F, Nieves J, Wilkinson C, Schnering D, Shen V, Lindsay R. Bone density change and biochemical indices of skeletal turnover. Calcif. Tissue Int. 1996; 58: 236–243
- Eyre D R, Koob T J, Van Ness K P. Quantitation of hydroxypyridinium crosslinks in collagen by high performance liquid chromatography. Anal. Biochem. 1984; 137: 380–388
- Steiger P, Cummings S R, Black D M, Spencer N E, Genant H K. Age-related decrements in bone mineral density in women over 65. J. Bone Miner. Res. 1992; 7: 625–632
- Orimo H, Shiraki M, Hayashi Y, Hoshino T, Onaya T, Miyazaki S, Kurosawa H, Nakamura T, Ogawa N. Effects of 1 α -hydroxyvitamin D3 on lumbar bone mineral density and vertebral fracture in patients with postmenopausal osteoporosis. Calcif. Tissue Int. 1994; 54: 370–376